This antibody was often found in patients with NMO, but very rarely in patients with other conditions (e.g. MS) and it was concluded that NMO-IgG is a specific and diagnostic marker autoantibody of NMO.9–11 Furthermore, myelin oligodendrocyte glycoprotein (MOG) autoantibodies have been extensively studied in experimental models of MS. This evidence concerns the gene MOG and myeloid sarcoma.